Medicine and Health Sciences Commons^™

A New Treatment For Psychosis In Parkinson’S Disease, Kevin J. Black

Kevin J. Black, MD

A Fixed-Dose Randomized Controlled Trial Of Olanzapine For Psychosis In Parkinson Disease, Michelle J. Nichols, Johanna M. Hartlein, Meredith Ga Eicken, Brad A. Racette, Kevin J. Black

Kevin J. Black, MD

Background: Psychosis is a common and debilitating side effect of long-term dopaminergic treatment of Parkinson disease (PD). While clozapine is an effective treatment, the need for blood monitoring has limited its first-line use.

Objective: Since olanzapine shows similar receptor affinity to clozapine, we hypothesized that it might be an effective alternative to clozapine for treatment of drug-induced psychosis (DIP) in PD, and that lower doses than usual might make it tolerable.

Methods: In 1998-2003 we conducted a four-week, double-blind, placebo-controlled, parallel group, fixed-dose trial of olanzapine (0, 2.5mg, or 5mg) in 23 PD patients with DIP while allowing for clinically …

Hallucinations—Psychosis Related To Parkinson’S Disease, Kevin J. Black

Kevin J. Black, MD

No abstract provided.